

Total Synthesis of a Frog Poison, ($\pm$)-Epibatidine, a Potent Non-opioid Analgesic

Kazuaki OKABE and Mitsutaka NATSUME*

Research Foundation Itsuu Laboratory, 2–28–10 Tamagawa, Setagaya-ku, Tokyo 158, Japan.

Received February 4, 1994; accepted March 11, 1994

A non-opioid analgesic, epibatidine (**1**), isolated from Ecuadoran poison frogs was synthesized in the racemic form starting from a readily available compound **2**. A partial Curtius rearrangement product **5** of **2** was converted into **12c** by way of the ketone **3** and its condensation product with the pyridine moiety **9c**, and catalytic hydrogenation of **12c** was specifically conducted in hydrochloric acid-containing 2-propanol for the preferential formation of an *exo*-product **15b**. Conversion of the substituent from **15b** to **15a** in a single operation using the Vilsmeier reagent, followed by deprotection of the *p*-toluenesulfonyl group with hydrobromic acid completed an eight-step synthesis of ($\pm$)-**1** from **2**.

Keywords total synthesis; poison frog constituent; epibatidine; non-opioid analgesic

Epibatidine (**1**) is a novel alkaloid isolated in a trace amount by Daly *et al.* in 1992 from Ecuadoran poison frog, *Epipedobates tricolor*, of the family Dendrobatidae.¹⁾ The chemical structure of **1** was determined by spectroscopic means without assignment of the absolute configuration. The preliminary biological tests showed **1** to be a non-opioid analgesic, 200–500 times as potent as morphine.¹⁾ Recently however, high toxicity of **1** to mice was reported.^{2a)} Several groups have recently reported total syntheses of **1**.²⁾ We have also been engaged in a synthetic study, and here we disclose our synthesis of ($\pm$)-**1**, according to the plan shown in Chart 1. Compound **2**³⁾ having σ symmetry is readily prepared from the Diels–Alder adduct⁴⁾ between 1-(*p*-toluenesulfonyl)pyrrole and dimethyl acetylenedicarboxylate, and should be available as a starting material for the enantioselective synthesis of either enantiomer of **1** by conducting a regioselective functionalization of the carboxylate groups in **2** using a chemical or enzymatic procedure. A possible method for the partial functionalization is the conversion of one of the two methyl carboxylates into a heteroatom group to furnish finally the ketone derivative **3**.⁵⁾ The requisite 3-pyridyl function can be introduced into this ketone group to afford ($\pm$)-epibatidine (**1**).

For that purpose, the diester **2** was cleanly hydrolyzed to a monoester **4** with 1 molar eq of lithium hydroxide in a mixture of 1,2-dimethoxyethane (DME) and water (2 : 1) at room temperature in 70% yield (Chart 2). This acid **4** was treated with diphenylphosphoryl azide⁶⁾ (DPPA) and triethylamine in a solution of *tert*-butanol and *N,N*-dimethylformamide (DMF) (1 : 1) at 80–85 °C for 13.5 h, and the Curtius rearrangement product **5** was produced in 75% yield. To perform a stereoselective introduction of the necessary 2-chloro-5-pyridyl moiety into the 7-azabicyclo[2.2.1]heptane system with *exo* configuration,

we initially planned the conjugate addition of a pyridyl anion to the α,β -unsaturated carboxylate **8**. Therefore, the carbamate **5** was catalytically hydrogenated over 10% palladium–carbon at a pressure of 3 atm at room temperature to afford **6** in 81% yield. A mild treatment of **6** with potassium carbonate in methanol at room temperature for 1 h gave an epimer **7** in a quantitative yield. However, attempted formation of the α,β -unsaturated ester **8** was unsuccessful under various conditions of base treatment for **6** and **7**.

Preparation of the ketone **3** was next tried aiming at a steady introduction of the pyridyl part into the bicyclo system (Chart 3). Formation of **3** was readily achieved in a single step and in 68% yield by heating a solution of **5** in a mixture of 2% hydrogen chloride-containing 1,4-dioxane and water (3 : 2) at *ca.* 80 °C for 14.5 h under an Ar atmosphere. Pyridyllithium derived from 3-bromopyridine or 5-bromo-2-chloropyridine⁷⁾ using butyllithium in diethyl ether was allowed to react with this ketone **3** at *ca.* –80 °C for 20 min to afford the condensation product **9a** or **9b** in 76% or 88% yield, respectively, accompanied with the formation of an epimer **10a** in 2% yield in the former case. Dehydration of **9a** and **9b** was carried out with thionyl chloride in the presence of pyridine or 2,6-lutidine at –20 °C to give **12a** and **12b**




Chart 1




Chart 2




Chart 3

in 55% and 56% yields. The by-products **13a** and **13b** were generated in 9% and 34% yields, respectively. Usual catalytic hydrogenation of **12a** over Raney nickel (W-2) in ethanol at room temperature afforded, as anticipated, an *endo*-product **10b** in 40% yield, together with an inseparable mixture of an *exo*-product and the recovery of **12a**. When **12b** was hydrogenated catalytically with either 10% palladium on carbon or platinum oxide, reductive dechlorination on the pyridine ring proceeded predominantly with little formation of the desired compound **15a**.

To avoid this difficulty, we finally adopted a synthetic scheme by way of the 2-methoxy-5-pyridyl derivative **15b**. A lithium salt prepared from 5-bromo-2-methoxypyridine⁸⁾ and butyllithium was condensed with the ketone **3** in tetrahydrofuran (THF) at *ca.* -75 °C for 20 min to provide **9c** in 89% yield. Along with the recovery of **3** in 5% yield, **11** was formed in 1% yield as a by-product, indicative of the generation of 5-bromo-3-lithio-2-methoxypyridine in a trace amount at the carbanion formation step. This time, use of thionyl chloride for the dehydration of **9c** gave **12c** in only 44% yield. A major product was **13c** (47% yield), probably originating from the corresponding chloro derivative, which was readily hydrolyzed during work-up *via* the oxonium salt **13c'**. Therefore the Burgess reagent⁹⁾ **14** was selected for the requisite dehydration reaction, and **12c** was obtained in 68% yield by refluxing a benzene solution of **9c** and **14** for 3 h under an Ar atmosphere. Since the usual hydrogenation of **12c** over 10% palladium-carbon in methanol afforded

15b and **16b** in 19% and 76% yields, respectively, improvement of the hydrogenation conditions was tried by carrying out the reaction in an acidic medium. This idea was based on the assumption that the protonic cation associated with an alcohol molecule would interact with the electron-rich double bond of **12c** at the more reactive *exo* face of the bicyclo framework, assisted by participation of the slightly basic tosylamide nitrogen, so as to regulate approach of the palladium catalyst from the *endo* side of **12c**, favoring the production of **15b**. So the catalytic hydrogenation was carried out in a *ca.* 1% hydrochloric acid-containing solution of methanol and water (11:1) at room temperature for 4 h. The production ratio of **15b** and **16b** was dramatically changed to 69% and 26% yields, respectively. In the case of the protonated form of an alcohol, use of 2-propanol, which is bulkier than methanol, would further block the double bond at the *exo* side of **12c**, and the best result was obtained by performing the same palladium-catalyzed hydrogenation as above in a solution of 2-propanol and water (12:1) containing *ca.* 1% hydrochloric acid, affording **15b** and **16b** in 72% and 22% yields, respectively.

Two steps remained for completion of the synthesis, *i.e.*, conversion of the methoxy group to the chlorine atom and removal of the tosyl protecting group. For the former process, a pathway by way of the pyridone **15c** had been considered, but we employed a direct method using the Vilsmeier reagent⁷⁾ for the transformation of **15b** into **15a**. When the methoxypyridines **15b** and **16b** were separately heated with the reagent in DMF at 95–99 °C

for 3.5–4 h, the chloropyridines **15a** and **16a** were produced in 70.5% and 67% yields, respectively, together with the pyridones **15c** (6% yield) and **16c** (6% yield) as well as the dimethylaminopyridines **15d** (3% yield) and **16d** (6% yield). As for the final step of removal of the protecting group, the usual procedure involving a reductive *N*-tosyl bond cleavage was not applicable in this case due to the presence of a reduction-sensitive 2-chloropyridine moiety. So rather drastic conditions using a commercial solution of 30% hydrobromic acid in acetic acid¹⁰ were introduced for that purpose. Deprotection of **16a** was achieved cleanly by stirring an ethyl acetate solution of **16a**, 30 molar eq of 30% hydrobromic acid in acetic acid, and *ca.* 5 molar eq of phenol at room temperature for 18 h. The expected product **17** was obtained in 71% yield, accompanied by the recovery of **16a** in 27% yield. The presence of phenol was essential for a clean reaction and good yield. By contrast, removal of the tosyl group from **15a** required forcing reaction conditions, *i.e.*, warming a chloroform solution of **15a** with the above amounts of 30% hydrobromic acid–acetic acid and phenol in a sealed tube at 55 °C for 18 h. The reaction products appeared complex on TLC, but after separation of **18a** (3% yield), **19a** (4% yield), and the recovery of **15a** (7% yield), a fraction containing ($\pm$)-**1** was found to be contaminated with **18b** and **19b**. Without further separation, this mixture was treated with lithium hydroxide in DME and water (2:1) at 55 °C for 15 h for recycling the bromoamines to the bicyclo system, and ($\pm$)-**1** was finally obtained in 76% yield. The ¹H- and ¹³C-NMR spectra of this compound were in good accordance with those described in the literature.^{2(c)}

In summary, a total synthesis of ($\pm$)-epibatidine (**1**) was accomplished in eight steps from a readily available compound **2** by way of **5**, **9c**, **12c**, **15b**, and **15a**. Enantioselective synthesis of the enantiomers of **1** is in progress.

Experimental

Melting points were determined on a Yanagimoto micro-melting point apparatus and are not corrected. MS and high-resolution MS (HRMS) were recorded on a Hitachi M-80B spectrometer at an ionizing voltage of 70 eV, and figures in parentheses indicate the relative intensities. IR spectra were measured on a Hitachi 215 spectrophotometer. ¹H-NMR spectra were obtained on a Varian EM 390 (90 MHz) spectrometer in CDCl₃ with TMS as an internal reference. ¹H-NMR (400 MHz) and ¹³C-NMR (100 MHz) spectra were measured on a JEOL JNM-GX-400 spectrometer. Column chromatography was conducted on silica gel, Fuji Davison BW 200 and preparative TLC (PTLC) was carried out on glass plates (20 × 20 cm) coated with Merck Silica gel 60 PF₂₅₄ (1 mm thick), unless otherwise specified. PTLC over alumina was carried out on glass plates (20 × 20 cm) coated with Merck Aluminum oxide 60 PF₂₅₄ (type E) (1 mm thick). Usual work-up refers to washing of the organic layers with water or brine, drying over anhydrous Na₂SO₄, and evaporating off the solvents under reduced pressure.

3-Methoxycarbonyl-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]hept-2-ene-2-carboxylic Acid (4**)** A solution of **2** (304 mg, 0.833 mmol) and LiOH·H₂O (35 mg, 0.83 mmol) in DME (10 ml) and H₂O (5 ml) was stirred at 20 °C for 1 h. After evaporation of the solvents under reduced pressure at 20 °C, 1 N HCl–H₂O (2 ml) was added and the whole was extracted with 10% MeOH–CH₂Cl₂. Usual work-up gave a residue (310 mg), which was separated by column chromatography [hexane–THF (2:1)→10% MeOH–CH₂Cl₂] over silica gel to afford crude **4** (48 mg) and crude **4** (222 mg). The former was purified by PTLC (CH₂Cl₂) to give recovery of **4** (35.5 mg, 12%). The latter afforded pure **4** (205 mg, 70%) after recrystallization from THF–hexane as colorless prisms, mp

155–157 °C. *Anal.* Calcd for C₁₆H₁₇NO₆S: C, 54.69; H, 4.88; N, 3.99. Found: C, 54.68; H, 4.94; N, 4.01. MS *m/z*: 323 (M⁺–H₂C=CH₂, 28), 155 (35), 151 (58), 91 (100), 65 (27). IR (KBr) cm^{−1}: 1725. ¹H-NMR (90 MHz) δ: 1.16–1.43 (2H, m), 2.10–2.54 (2H, m), 2.43 (3H, s), 3.90 (3H, s), 4.94–5.19 (2H, m), 7.26 and 7.55 (A₂B₂, *J*=8 Hz).

Methyl 3-(*tert*-Butyloxycarbonyl)amino-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]hept-2-ene-2-carboxylate (5**)** DPPA (0.18 ml, 0.84 mmol) was added to a solution of **4** (84.5 mg, 0.24 mmol) and Et₃N (0.13 ml, 0.93 mmol) in *tert*-BuOH (5 ml) and DMF (5 ml), and the mixture was heated under an Ar atmosphere at 80–85 °C for 13.5 h, then cooled to 0 °C. Saturated NaHCO₃–H₂O was added and the whole was extracted with Et₂O, and worked up as usual. Separation by PTLC [hexane–EtOAc (3:1)] gave crude **5** (84 mg), which was further purified by PTLC (CH₂Cl₂) to give **5** (76.5 mg, 75%) as a colorless syrup. MS *m/z*: 394 (M⁺–H₂C=CH₂, 13), 338 (11), 294 (51), 139 (70), 107 (20), 91 (48), 57 (100), 41 (40). IR (CHCl₃) cm^{−1}: 1745, 1733, 1680, 1625. ¹H-NMR (90 MHz) δ: 1.28–1.46 (2H, m), 1.50 (9H, s), 1.97–2.35 (2H, m), 2.40 (3H, s), 3.64 (3H, s), 4.79–4.92 (1H, m), 5.62–5.76 (1H, m), 7.17 and 7.58 (A₂B₂, *J*=8.5 Hz), 8.24 (1H, br s).

Methyl endo-3-(*tert*-Butyloxycarbonyl)amino-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane-endo-2-carboxylate (6**)** A suspension of **5** (22 mg, 0.052 mmol) and 10% Pd–C (12 mg) in MeOH (16 ml) was vigorously stirred under H₂ (3 atm) at 26 °C for 4 h. The catalyst was removed by filtration, and the filtrate was concentrated *in vacuo* to afford a residue (22 mg). This was purified by PTLC [hexane–EtOAc (3:1)] to give **6** (18 mg, 81%) as a colorless syrup. MS *m/z*: 351 (M⁺–*tert*-BuO, 2), 223 (21), 102 (25), 91 (24), 68 (100), 57 (55), 41 (23). IR (CHCl₃) cm^{−1}: 1732, 1712. ¹H-NMR (90 MHz) δ: 1.42 (9H, s), *ca.* 1.50–2.00 (4H, m), 2.44 (3H, s), 3.09–3.40 (1H, m), 3.70 (3H, s), 3.99–4.53 (3H, m), 6.48 (1H, br d, *J*=6 Hz), 7.25 and 7.80 (A₂B₂, *J*=8.5 Hz).

Methyl endo-3-(*tert*-Butyloxycarbonyl)amino-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane-*exo*-2-carboxylate (7**)** A mixture of **6** (9 mg, 0.02 mmol) and anhydrous K₂CO₃ (15 mg, 0.11 mmol) in MeOH (2 ml) was stirred at 25 °C for 1 h. Saturated NH₄Cl–H₂O was added and the whole was extracted with CH₂Cl₂, and worked up as usual. Purification by PTLC (CH₂Cl₂) gave **7** (9 mg, 100%) as a colorless syrup. MS *m/z*: 351 (M⁺–*tert*-BuO, 1), 223 (12), 102 (31), 91 (23), 68 (100), 57 (43), 41 (20). IR (CHCl₃) cm^{−1}: 1740, 1714. ¹H-NMR (90 MHz) δ: 1.45 (9H, s), *ca.* 1.48–2.23 (5H, m), 2.42 (3H, s), 3.65 (3H, s), 4.12–4.58 (3H, m), 4.58–5.00 (1H, m), 7.26 and 7.78 (A₂B₂, *J*=8.5 Hz).

7-(*p*-Toluenesulfonyl)-7-azabicyclo[2.2.1]heptan-2-one (3**)** A solution of **5** (248 mg, 0.588 mmol) in freshly distilled 1,4-dioxane (10.5 ml) containing 5% HCl–H₂O (7 ml) was stirred under an Ar atmosphere at *ca.* 80 °C for 14.5 h, and allowed to cool. H₂O was added and the whole was extracted with CH₂Cl₂. The CH₂Cl₂ solution was washed with saturated NaHCO₃–H₂O and worked up as usual to leave a residue (172 mg). Purification by PTLC [hexane–CH₂Cl₂ (1:3)], followed by recrystallization from CH₂Cl₂–MeOH gave **3** (105.5 mg, 68%) as colorless needles, mp 135–136 °C. *Anal.* Calcd for C₁₃H₁₅NO₃S: C, 58.55; H, 5.70; N, 5.28. Found: C, 58.82; H, 5.71; N, 5.23. MS *m/z*: 237 (M⁺–H₂C=CH₂, 28), 155 (20), 105 (49), 91 (100), 82 (46), 68 (36), 65 (34), 55 (60), 41 (42), 39 (31). IR (KBr) cm^{−1}: 1765. ¹H-NMR (400 MHz) δ: 1.56–1.68 (2H, m), 1.93 (1H, d, *J*=17.5 Hz), 2.05–2.19 (2H, m), 2.35–2.45 (1H, m), 2.44 (3H, s), 4.07–4.13 (1H, m), 4.56–4.62 (1H, m), 7.32 and 7.77 (A₂B₂, *J*=8 Hz).

endo-2-Hydroxy-*exo*-2-(3-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (9a**) and *exo*-2-Hydroxy-endo-2-(3-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (**10a**)** BuLi in hexane (1.6 M, 0.75 ml, 1.20 mmol) was added to a pre-cooled (−80 °C) solution of 3-bromopyridine (0.12 ml, 1.23 mmol) in Et₂O (3.5 ml), and the solution was stirred under an Ar atmosphere at −80 °C for 10 min. A solution of **3** (106.5 mg, 0.402 mmol) in THF (2.5 ml) was added to the above solution, and the mixture was stirred under an Ar atmosphere at −80–−76 °C for 20 min. Saturated NH₄Cl–H₂O was added and the whole was extracted with 10% MeOH–CH₂Cl₂, then worked up as usual to give a residue (196 mg). Separation by PTLC [hexane–EtOAc (2:7)], followed by purification using PTLC (3% MeOH–CH₂Cl₂) gave **9a** (104.5 mg, 76%) and **10a** (3 mg, 2%). Purification using PTLC [hexane–CH₂Cl₂ (1:3) and then hexane–EtOAc (2:1)] afforded recovered **3** (5.5 mg, 5%). **9a**: Colorless syrup. MS *m/z*: 189 (M⁺–Ts, 65), 122 (40), 106 (17), 91 (29), 78 (22), 68 (100). ¹H-NMR (90 MHz) δ: 1.39–1.95 (4H, m), 2.09–2.62 (2H, m), 2.41 (3H, s), 3.98–4.46 (2H + OH, m), 7.10 (1H, dd, *J*=8, 4.5 Hz), 7.22 and 7.66 (A₂B₂, *J*=8 Hz), 7.77–7.97 (1H, m), 8.07–8.29 (1H, m), 8.46–8.64 (1H, m). **10a**:

Colorless syrup. MS m/z : 189 ($M^+ - Ts$, 59), 122 (38), 106 (17), 91 (29), 78 (21), 68 (100). 1H -NMR (90 MHz) δ : 2.45 (3H, s), 4.12–4.26 (1H, m), 4.33–4.50 (1H, m), 7.17–7.48 (1H, m), 7.30 and 7.84 (A_2B_2 , $J=8.5$ Hz), 7.71–7.98 (1H, m), 8.40–8.84 (2H, m).

exo-2-(2-Chloro-5-pyridyl)-endo-2-hydroxyl-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (9b) A solution of **3** (55.5 mg, 0.21 mmol) in THF (2.5 ml) was added to a solution of 2-chloro-5-lithiopyridine, prepared as above from 5-bromo-2-chloropyridine (123 mg, 0.634 mmol) and 1.6 M BuLi in hexane (0.33 ml, 0.53 mmol) in Et₂O (2.5 ml), and the mixture was stirred under an Ar atmosphere at -76 – -74 °C for 20 min. Work-up as above, followed by purification using PTLC [hexane–EtOAc (2:1) and 2.5% MeOH–CH₂Cl₂] afforded **9b** (69.5 mg, 88%) along with the recovery of **3** (5 mg, 9%). **9b**: Colorless syrup. MS m/z : 225 (12) and 223 (37) ($M^+ - Ts$), 158 (3) and 156 (9), 142 (4) and 140 (12), 114 (3) and 112 (8), 91 (30), 68 (100), 41 (17). 1H -NMR (90 MHz) δ : 1.36–1.90 (4H, m), 2.11–2.59 (2H, m), 2.41 (3H, s), 3.86 (1H, brs, OH), 4.01–4.15 (1H, m), 4.15–4.34 (1H, m), 7.10 (1H, d, $J=9$ Hz), 7.23 and 7.64 (A_2B_2 , $J=8$ Hz), 7.78 (1H, dd, $J=9$, 2.5 Hz), 8.37 (1H, d, $J=2.5$ Hz).

endo-2-Hydroxy-exo-2-(2-methoxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (9c) and exo-2-(5-Bromo-2-methoxy-3-pyridyl)-endo-2-hydroxy-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (11) Similarly reaction of **3** (257 mg, 0.970 mmol) in THF (7 ml) with 5-lithio-2-methoxypyridine, prepared from 5-bromo-2-methoxypyridine (547 mg, 2.91 mmol) and 1.6 M BuLi in hexane (1.50 ml, 2.40 mmol) in THF (8 ml), gave **9c** (323.5 mg, 89%) and **11** (5 mg, 1%), along with recovery of **3** (12.5 mg, 5%). **9c**: Colorless syrup. MS m/z : 219 ($M^+ - Ts$, 52), 152 (64), 136 (14), 91 (27), 68 (100). 1H -NMR (90 MHz) δ : 1.42–1.99 (4H, m), 2.17–2.66 (2H + OH, m), 2.42 (3H, s), 3.89 (3H, s), 4.06–4.33 (2H, m), 6.55 (1H, d, $J=9$ Hz), 7.22 and 7.64 (A_2B_2 , $J=8$ Hz), 7.55–7.77 (1H, m), 8.20 (1H, d, $J=3$ Hz). **11**: Colorless syrup. MS m/z : 299 (18) and 297 (17) ($M^+ - Ts$), 234 (6) and 232 (5), 216 (4) and 214 (4), 91 (20), 68 (100). 1H -NMR (90 MHz) δ : 1.46–2.12 (4H, m), 2.17–2.64 (2H, m), 2.42 (3H, s), 3.98 (3H, s), 4.06–4.36 (2H, m), 4.14 (1H, brs, OH), 7.21 and 7.61 (A_2B_2 , $J=8.5$ Hz), 7.53 (1H, d, $J=2.5$ Hz), 8.04 (1H, d, $J=2.5$ Hz).

2-(3-Pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (12a) and exo-2-Chloro-endo-2-(3-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (13a) SOCl₂ (0.50 ml, 6.85 mmol) was added at -20 °C to a solution of **9a** (102.5 mg, 0.298 mmol) in pyridine (4 ml), and the mixture was stirred under an Ar atmosphere at the same temperature for 30 min. Saturated NaHCO₃–H₂O was added and the whole was extracted with 10% MeOH–CH₂Cl₂, and worked up as usual. Separation by PTLC [hexane–EtOAc (2:3)] gave **12a** (54 mg) and **13a** (9.5 mg, 9%). The former was purified by recrystallization from THF–hexane to afford **12a** (53 mg, 55%) as colorless needles, mp 155–156.5 °C. *Anal.* Calcd for C₁₈H₁₈N₂O₂S: C, 66.23; H, 5.56; N, 8.58. Found: C, 66.17; H, 5.64; N, 8.53. HRMS Calcd for C₁₈H₁₈N₂O₂S: 326.1088. Found: 326.1098. MS m/z : 326 (M^+ , 1), 298 (84), 171 (13), 155 (40), 143 (21), 91 (100), 65 (25). 1H -NMR (90 MHz) δ : 1.00–1.52 (2H, m), 2.03–2.45 (2H, m), 2.29 (3H, s), 4.71–4.87 (1H, m), 4.93–5.08 (1H, m), 6.02 (1H, d, $J=2$ Hz), 7.04 and 7.52 (A_2B_2 , $J=8$ Hz), 7.04–7.41 (2H, m), 8.19–8.36 (1H, m), 8.36–8.56 (1H, m). **13a**: Colorless syrup. HRMS Calcd for C₁₈H₁₉³⁷ClN₂O₂S and C₁₈H₁₉³⁵ClN₂O₂S: 364.0825 and 362.0855. Found: 364.0853 and 362.0871. MS m/z : 364 (4) and 362 (8) (M^+), 298 (7), 223 (31), 209 (6) and 207 (17), 142 (12) and 140 (34), 91 (53), 68 (100), 65 (21), 41 (30). 1H -NMR (90 MHz) δ : 1.54–2.30 (4H, m), 2.41 (3H, s), 2.50–3.09 (2H, m), 4.22–4.41 (1H, m), 4.50–4.64 (1H, m), 7.05–7.32 (1H, m), 7.19 and 7.57 (A_2B_2 , $J=8.5$ Hz), 7.59–7.86 (1H, m), 8.37–8.59 (1H, m), 8.65–8.88 (1H, m).

2-(2-Chloro-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (12b) and exo-2-Chloro-endo-2-(2-chloro-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (13b) In the same manner as described above, **9b** (8.5 mg, 0.02 mmol) was treated with SOCl₂ (33 μ l, 0.45 mmol) in the presence of 2,6-lutidine (0.10 ml, 0.86 mmol) in CH₂Cl₂ (2 ml) to afford **12b** (4.5 mg, 56%) and **13b** (3 mg, 34%). **12b**: Colorless syrup. MS m/z : 362 (0.7) and 360 (1.4) (M^+), 334 (21) and 332 (54), 207 (3) and 205 (9), 179 (5) and 177 (13), 155 (40), 91 (100), 68 (15), 65 (29), 41 (22). 1H -NMR (90 MHz) δ : 1.06–1.44 (2H, m), 2.04–2.48 (2H, m), 2.34 (3H, s), 4.70–4.80 (1H, m), 4.80–5.04 (1H, m), 6.03 (1H, d, $J=2.5$ Hz), 7.07 (1H, brd, $J=8$ Hz), 7.17–7.38 (1H, m), 7.17 and 7.52 (A_2B_2 , $J=8.5$ Hz), 7.99–8.11 (1H, m). **13b**: Colorless syrup. HRMS Calcd for C₁₈H₁₈³⁷Cl₂N₂O₂S, C₁₈H₁₈³⁷Cl₂N₂O₂S and C₁₈H₁₉³⁵Cl₂N₂O₂S: 400.0406, 398.0435 and 396.0465. Found: 400.0396, 398.0425 and 396.0448. MS m/z : 400 (1), 398 (4) and 396 (6) (M^+); 334

(2) and 332 (4); 245 (1), 243 (7) and 241 (10); 223 (25); 180 (2) and 178 (6); 178 (6), 176 (9) and 174 (12); 155 (11); 91 (51); 68 (100); 65 (18); 41 (32). 1H -NMR (90 MHz) δ : 2.41 (3H, s), 2.51–3.01 (2H, m), 4.23–4.49 (2H, m), 7.13 (1H, d, $J=2.5$ Hz), 7.19 and 7.55 (A_2B_2 , $J=8.5$ Hz), 7.67 (1H, dd, $J=8.5$, 2.5 Hz), 8.42 (1H, d, $J=2.5$ Hz).

2-(2-Methoxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]hept-2-ene (12c) (i) With Burgess Reagent: Commercial 97% Burgess reagent (203 mg, 0.826 mmol) was added to a solution of **9c** (154.5 mg, 0.413 mmol) in benzene (15 ml) and the mixture was heated under an Ar atmosphere at 87–90 °C for 3 h, then allowed to cool. H₂O was added and the whole was extracted with Et₂O, and worked up as usual. Purification by column chromatography over silica gel [hexane–EtOAc (5:2)], followed by recrystallization from THF–hexane afforded **12c** (100 mg, 68%) as colorless prisms, mp 145–147 °C or needles, mp 126–128 °C. *Anal.* Calcd for C₁₉H₂₀N₂O₃S: C, 64.03; H, 5.66; N, 7.86. Found: C, 64.03; H, 5.68; N, 7.80. HRMS Calcd for C₁₉H₂₀N₂O₃S: 356.1193. Found: 356.1189. MS m/z : 356 (M^+ , 2), 328 (89), 201 (16), 173 (100), 91 (49), 65 (23). 1H -NMR (90 MHz) δ : 1.04–1.40 (2H, m), 1.97–2.39 (2H, m), 2.29 (3H, s), 3.90 (3H, s), 4.65–4.85 (1H, m), 4.85–5.02 (1H, m), 5.79 (1H, d, $J=2.5$ Hz), 6.58 (1H, d, $J=8.5$ Hz), 7.04 and 7.51 (A_2B_2 , $J=8$ Hz), 7.15 (1H, dd, $J=8.5$, 2.5 Hz), 7.87 (1H, d, $J=2.5$ Hz).

(ii) With SOCl₂: In the same manner as described for the preparation of **12a**, **9c** (9.5 mg, 0.025 mmol) was treated with SOCl₂ (40 μ l, 0.55 mmol) in the presence of 2,6-lutidine (0.13 ml, 1.12 mmol) in CH₂Cl₂ (2 ml) to afford **12c** (4 mg, 44%) and *exo-2-hydroxy-endo-2-(2-methoxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (13c)* (4.5 mg, 47%) as a colorless syrup. **13c**: MS m/z : 219 ($M^+ - Ts$, 46), 152 (61), 136 (14), 91 (27), 68 (100), 41 (14). 1H -NMR (90 MHz) δ : 1.04–1.95 (4H, m), 2.08–2.28 (2H, m), 2.44 (3H, s), 3.14 (1H, brs, OH), 3.91 (3H, s), 4.09–4.25 (1H, m), 4.28–4.50 (1H, m), 6.71 (1H, d, $J=8.5$ Hz), 7.30 and 7.84 (A_2B_2 , $J=8.5$ Hz), 7.63 (1H, dd, $J=8.5$, 2.5 Hz), 8.15 (1H, d, $J=2.5$ Hz).

exo-2-(2-Methoxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (15b) and endo-2-(2-Methoxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (16b) A solution of **12c** (62.5 mg, 0.18 mmol) in 2-propanol (17.5 ml) and 10% HCl (1.5 ml) was hydrogenated with 10% Pd–C (28.5 mg) at 19 °C for 4 h. The catalyst was removed by filtration, and the filtrate was evaporated under reduced pressure. Saturated NaHCO₃–H₂O was added and the whole was extracted with CH₂Cl₂, and worked up as usual. Separation and purification by PTLC [hexane–DME (4:1) and hexane–EtOAc (4:1)] afforded **15b** (45 mg) and **16b** (14 mg, 22%). The former was recrystallized from CH₂Cl₂–MeOH to give **15b** (45 mg, 72%) as colorless needles, mp 127–128 °C. *Anal.* Calcd for C₁₉H₂₂N₂O₃S: C, 63.67; H, 6.18; N, 7.82. Found: C, 63.56; H, 6.22; N, 7.71. HRMS Calcd for C₁₉H₂₂N₂O₃S: 358.1350. Found: 358.1339. MS m/z : 358 (M^+ , 11), 223 (8), 203 (100), 136 (86), 122 (33), 91 (46), 68 (97), 41 (52). 1H -NMR (400 MHz) δ : 1.43–1.61 (2H, m), 1.76–1.89 (3H, m), 1.95 (1H, dd, $J=12.5$, 9 Hz), 2.43 (3H, s), 2.77 (1H, dd, $J=9$, 5 Hz), 3.90 (3H, s), 4.06 (1H, d, $J=3.5$ Hz), 4.34 (1H, dd, $J=4$, 4 Hz), 6.60 (1H, d, $J=9$ Hz), 7.29 and 7.79 (A_2B_2 , $J=8$ Hz), 7.54 (1H, dd, $J=9$, 2.5 Hz), 7.91 (1H, d, $J=2.5$ Hz). **16b**: Colorless syrup. HRMS Calcd for C₁₉H₂₂N₂O₃S: 358.1350. Found: 358.1363. MS m/z : 358 (M^+ , 12), 223 (10), 203 (100), 136 (85), 122 (37), 91 (45), 68 (100), 41 (47). 1H -NMR (400 MHz) δ : 1.37–1.52 (2H, m), 1.52–1.62 (1H, m), 1.57 (1H, dd, $J=12$, 5.5 Hz), 1.76–1.87 (1H, m), 2.32 (1H, dddd, $J=12$, 12, 5, 3 Hz), 2.43 (3H, s), 3.49–3.57 (1H, m), 3.91 (3H, s), 4.27 (1H, dd, $J=5$, 5 Hz), 4.30 (1H, dd, $J=5$, 5 Hz), 6.71 (1H, d, $J=8.5$ Hz), 7.31 and 7.85 (A_2B_2 , $J=8$ Hz), 7.36 (1H, dd, $J=8.5$, 2 Hz), 7.98 (1H, d, $J=2$ Hz).

exo-2-(2-Chloro-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (15a) A solution of **15b** (49 mg, 0.14 mmol) in DMF (4 ml) was cooled at 0 °C and POCl₃ (0.38 ml, 4.08 mmol) was added. The mixture was stirred under an Ar atmosphere at 0 °C for 1 h, and heated at 95–99 °C for 3.5 h, then allowed to cool. Saturated NaHCO₃–H₂O was carefully added and the whole was extracted with Et₂O, and worked up as usual. Separation of the residue (66 mg) by PTLC [hexane–CH₂Cl₂ (1:4)] afforded crude **15a** (36 mg), crude **15c** (3.5 mg) and crude **15d** (13.5 mg). Crude **15a** was recrystallized from benzene–hexane to give **15a** (35 mg, 70.5%) as colorless prisms, mp 134–135 °C. *Anal.* Calcd for C₁₈H₁₉ClN₂O₂S: C, 59.58; H, 5.27; N, 7.72. Found: C, 59.72; H, 5.31; N, 7.69. HRMS Calcd for C₁₈H₁₉³⁷ClN₂O₂S and C₁₈H₁₉³⁵ClN₂O₂S: 364.0825 and 362.0855. Found: 364.0837 and 362.0836. MS m/z : 364 (6) and 362 (14) (M^+), 223 (21), 209 (8) and 207 (21), 142 (9) and 140 (25),

91 (45), 68 (100), 65 (19), 41 (39). ¹H-NMR (400 MHz) δ : 1.45–1.62 (2H, m), 1.76–1.92 (3H, m), 1.99 (1H, dd, J = 12, 9 Hz), 2.44 (3H, s), 2.83 (1H, dd, J = 9, 5 Hz), 4.10 (1H, br d, J = 3.5 Hz), 4.36 (1H, dd, J = 4, 4 Hz), 7.18 (1H, d, J = 8.5 Hz), 7.30 and 7.78 (A₂B₂, J = 8 Hz), 7.63 (1H, dd, J = 8.5, 3 Hz), 8.16 (1H, d, J = 3 Hz). Crude **15c** was purified by PTLC (3% MeOH–CH₂Cl₂) to afford *exo*-2-(2-hydroxy-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (**15c**) (3 mg, 6%) as a colorless amorphous powder. HRMS Calcd for C₁₈H₂₀N₂O₃S: 344.1193. Found: 344.1208. MS m/z : 344 (M⁺, 14), 223 (9), 189 (89), 122 (67), 108 (16), 91 (44), 68 (100), 65 (21), 41 (38). IR (KBr) cm⁻¹: 1667, 1620. ¹H-NMR (400 MHz) δ : 1.42–1.57 (2H, m), 1.69–1.78 (1H, m), 1.78–1.91 (2H, m), 1.90 (1H, dd, J = 12.5, 9 Hz), 2.42 (3H, s), 2.59 (1H, dd, J = 9, 5 Hz), 3.97–4.02 (1H, m), 4.32–4.37 (1H, m), 6.45 (1H, d, J = 10 Hz), 7.11 (1H, d, J = 2.5 Hz), 7.31 and 7.78 (A₂B₂, J = 8 Hz), 7.44 (1H, dd, J = 10, 2.5 Hz). Crude **15d** was purified by PTLC [hexane–EtOAc (3:2)] to afford *exo*-2-(2-dimethylamino-5-pyridyl)-7-(*p*-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (**15d**) (1.5 mg, 3%) as a colorless syrup. HRMS Calcd for C₂₀H₂₅N₃O₂S: 371.1666. Found: 371.1667. MS m/z : 371 (M⁺, 10), 216 (100), 149 (37), 135 (21), 133 (12), 119 (22), 91 (36), 68 (19), 65 (15), 41 (17). ¹H-NMR (90 MHz) δ : 1.32–2.13 (6H, m), 2.43 (3H, s), 2.69 (1H, dd, J = 8, 5 Hz), 3.06 (6H, s), 3.99–4.13 (1H, m), 4.21–4.39 (1H, m), 6.39 (1H, d, J = 9 Hz), 7.26 and 7.79 (A₂B₂, J = 8.5 Hz), 7.45 (1H, dd, J = 9, 2.5 Hz), 7.92 (1H, d, J = 2.5 Hz).

endo-2-(2-Chloro-5-pyridyl)-7-(p-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (16a) In the same manner as described above, treatment of **16b** (40.5 mg, 0.11 mmol) with POCl₃ (0.32 ml, 3.43 mmol) in DMF (3.5 ml) gave **16a** (27.5 mg, 67%), **16c** (2.5 mg, 6%) and **16d** (2.5 mg, 6%). **16a**: Colorless syrup. HRMS Calcd for C₁₈H₁₉³⁷ClN₂O₂S and C₁₈H₁₉³⁵ClN₂O₂S: 364.0825 and 362.0855. Found: 364.0847 and 362.0875. MS m/z : 364 (5) and 362 (9) (M⁺), 223 (17), 209 (7) and 207 (16), 142 (7) and 140 (21), 91 (31), 68 (100), 65 (13), 41 (36). ¹H-NMR (400 MHz) δ : 1.36–1.47 (2H, m), 1.54–1.68 (1H, m), 1.61 (1H, dd, J = 12.5, 5.5 Hz), 1.77–1.90 (1H, m), 2.40 (1H, dddd, J = 12.5, 12, 5, 3 Hz), 2.44 (3H, s), 3.57–3.66 (1H, m), 4.30 (1H, dd, J = 5, 5 Hz), 4.35 (1H, dd, J = 5, 5 Hz), 7.29 (1H, d, J = 8 Hz), 7.32 and 7.84 (A₂B₂, J = 8 Hz), 7.45 (1H, dd, J = 8, 3 Hz), 8.22 (1H, d, J = 3 Hz). **endo-2-(2-Hydroxy-5-pyridyl)-7-(p-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (16c)**: Colorless prisms, mp 228–229 °C (CH₂Cl₂–MeOH). Anal. Calcd for C₁₈H₂₀N₂O₃S: C, 62.77; H, 5.85; N, 8.13. Found: C, 62.61; H, 5.88; N, 8.13. HRMS Calcd for C₁₈H₂₀N₂O₃S: 344.1193. Found: 344.1204. MS m/z : 344 (M⁺, 10), 223 (8), 189 (68), 122 (57), 108 (14), 91 (43), 68 (100), 65 (23), 41 (39). IR (KBr) cm⁻¹: 1654, 1620. ¹H-NMR (400 MHz) δ : 1.30–1.40 (1H, m), 1.36 (1H, dd, J = 12.5, 5.5 Hz), 1.41–1.51 (1H, m), 1.53–1.64 (1H, m), 1.74–1.87 (1H, m), 2.27 (1H, dddd, J = 12.5, 11.5, 4.5, 3.5 Hz), 2.44 (3H, s), 3.32–3.40 (1H, m), 4.24 (1H, dd, J = 4.5, 4.5 Hz), 4.25 (1H, dd, J = 4.5, 4.5 Hz), 6.56 (1H, d, J = 9.5 Hz), 7.18 (1H, d, J = 2.5 Hz), 7.30 and 7.82 (A₂B₂, J = 8.5 Hz), 7.31 (1H, dd, J = 9.5, 2.5 Hz). **endo-2-(2-Dimethylamino-5-pyridyl)-7-(p-toluenesulfonyl)-7-azabicyclo[2.2.1]heptane (16d)**: Colorless syrup. HRMS Calcd for C₂₀H₂₅N₃O₂S: 371.1666. Found: 371.1663. MS m/z : 371 (M⁺, 10), 216 (100), 149 (33), 135 (20), 133 (12), 119 (19), 91 (29), 68 (20), 65 (11), 41 (14). ¹H-NMR (90 MHz) δ : 1.17–2.06 (5H, m), 2.06–2.52 (1H, m), 2.43 (3H, s), 3.06 (6H, s), 3.26–3.66 (1H, m), 4.16–4.36 (2H, m), 6.50 (1H, d, J = 9 Hz), 7.26 (1H, dd, J = 9, 2.5 Hz), 7.32 and 7.81 (A₂B₂, J = 8.5 Hz), 8.02 (1H, d, J = 2.5 Hz).

endo-1-(2-Chloro-5-pyridyl)-7-azabicyclo[2.2.1]heptane (17) Commercially available 30% HBr–AcOH (0.25 ml) was added to a solution of **16a** (11 mg, 0.030 mmol) and phenol (15 mg, 0.16 mmol) in EtOAc (2 ml). The flask was firmly stoppered and the mixture was stirred at 24 °C for 18 h. NaOH (3 N, 4.5 ml) was added and the whole was extracted with CH₂Cl₂, and worked up as usual. Separation by PTLC (10% MeOH–CH₂Cl₂) gave crude **17** (6 mg) and crude **16a**; the latter was purified by PTLC [hexane–EtOAc (7:2)] to give the recovery of **16a** (3 mg, 27%). The former, probably in the form of a silica acid salt in part, was made free by addition of 3 N NaOH (1 ml), and shaken thoroughly with H₂O (4 ml) and CH₂Cl₂. Usual work-up and purification by Al₂O₃ PTLC (0.5% MeOH–CH₂Cl₂) gave **17** (4.5 mg, 71%) as a colorless syrup. HRMS Calcd for C₁₁H₁₃³⁷ClN₂ and C₁₁H₁₃³⁵ClN₂: 210.0737 and 208.0767. Found: 210.0746 and 208.0759. MS m/z : 210 (2) and 208 (5) (M⁺), 142 (3) and 140 (8), 104 (3), 69 (100), 68 (46). ¹H-NMR (400 MHz) δ : 1.32–1.48 (3H, m), 1.52 (1H, dd, J = 12.5, 5.5 Hz), 1.59–1.73 (1H, m), 2.14 (1H, dddd, J = 12.5, 12, 5, 3 Hz), 3.28–3.37 (1H, m), 3.79 (1H, dd, J = 5, 5 Hz), 3.80 (1H, dd, J = 5, 5 Hz), 7.28 (1H,

d, J = 8 Hz), 7.48 (1H, dd, J = 8, 2.5 Hz), 8.25 (1H, d, J = 2.5 Hz). ¹³C-NMR (100 MHz) δ : 24.0, 30.9, 34.8, 44.7, 57.5, 61.1, 123.8, 135.7, 138.4, 149.1, 149.5.

(±)-Epibatidine (1) A solution of **15a** (28.5 mg, 0.079 mmol), phenol (41 mg, 0.44 mmol) and 30% HBr–AcOH (0.64 ml) in CHCl₃ (5.5 ml) was heated in a sealed tube at ca. 55 °C for 18 h, and allowed to cool. NaOH (3 N, 15 ml) was added and the whole was extracted with CH₂Cl₂, and worked up as usual. Separation by PTLC (5% MeOH–CH₂Cl₂) gave a mixture (16 mg) of **1**, **18b** and **19b**, accompanied by a mixture (14.5 mg) of **15a**, **18a** and **19a**. The former mixture was dissolved in a solution of DME (3 ml) and H₂O (1.5 ml) containing LiOH·H₂O (35 mg), and the solution was stirred at ca. 55 °C for 15 h. After evaporation of the solvents under reduced pressure at 20 °C, H₂O (3 ml) was added and the whole was extracted with CH₂Cl₂, then worked up as usual. Purification by Al₂O₃ PTLC [hexane–CH₂Cl₂ (1:3)] gave (±)-**1** (12.5 mg, 76%) as a colorless syrup. HRMS Calcd for C₁₁H₁₃³⁷ClN₂ and C₁₁H₁₃³⁵ClN₂: 210.0737 and 208.0767. Found: 210.0728 and 208.0768. MS m/z : 210 (2) and 208 (6) (M⁺), 181 (1) and 179 (3), 142 (3) and 140 (7), 69 (100), 68 (44). ¹H-NMR (400 MHz) δ : 1.45–1.67 (5H, m), 1.92 (1H, dd, J = 12, 9 Hz), 2.77 (1H, dd, J = 9, 5 Hz), 3.54–3.59 (1H, m), 3.78–3.83 (1H, m), 7.24 (1H, d, J = 8 Hz), 7.78 (1H, dd, J = 8, 2.5 Hz), 8.28 (1H, d, J = 2.5 Hz). ¹³C-NMR (100 MHz) δ : 30.1, 31.3, 40.3, 44.5, 56.4, 62.8, 123.9, 137.7, 141.0, 148.8, 148.9. The mixture of **15a**, **18a** and **19a** was further separated by PTLC [hexane–EtOAc (2:1)] to give **19a** (1.5 mg, 4%) and a mixture of **15a** and **18a**. This mixture was separated by PTLC [hexane–CH₂Cl₂ (1:3)] to afford recovered **15a** (2 mg, 7%) and **18a** (1 mg, 3%). **18a**: Colorless syrup. MS m/z : 446 (4), 444 (12) and 442 (9) (M⁺); 365 (4) and 363 (10); 291 (3), 289 (10) and 287 (7); 237 (2), 235 (6) and 233 (5); 209 (4) and 207 (11); 155 (19); 142 (18) and 140 (54); 129 (11) and 127 (35); 91 (100); 65 (32); 41 (17); 39 (17). ¹H-NMR (400 MHz) δ : 1.98–2.14 (4H, m), 2.14–2.32 (2H, m), 2.46 (3H, s), 3.45 (1H, ddd, J = 13, 3.5, 3.5 Hz), 3.49–3.55 (1H, m), 4.61 (1H, d, J = 7 Hz, NH), 4.79–4.84 (1H, m), 6.94 (1H, d, J = 8.5 Hz), 7.14 (1H, dd, J = 8.5, 3 Hz), 7.14 and 7.31 (A₂B₂, J = 8 Hz), 7.93 (1H, d, J = 3 Hz). **19a**: Colorless syrup. MS m/z : 446 (7), 444 (22) and 442 (16) (M⁺); 365 (4) and 363 (9); 323 (3) and 321 (8); 291 (1), 289 (4) and 287 (3); 209 (2) and 207 (5); 194 (4) and 192 (11); 155 (30); 91 (100); 65 (24); 41 (11); 39 (13). ¹H-NMR (400 MHz) δ : 1.38 (1H, dddd, J = 13, 12, 12, 4 Hz), 1.47 (1H, ddd, J = 13, 12, 12 Hz), 1.88–2.02 (2H, m), 2.11 (1H, dddd, J = 13, 4, 3, 3 Hz), 2.43 (3H, s), 2.47 (1H, dddd, J = 13.5, 4, 4, 3 Hz), 2.87 (1H, ddd, J = 12, 12, 3 Hz), 3.32 (1H, dddd, J = 12, 12, 8, 4, 4 Hz), 3.88 (1H, ddd, J = 12, 12, 4 Hz), 4.65 (1H, d, J = 8 Hz, NH), 7.28 (1H, d, J = 8 Hz), 7.31 and 7.75 (A₂B₂, J = 8 Hz), 7.41 (1H, dd, J = 8, 2.5 Hz), 8.18 (1H, d, J = 2.5 Hz).

Acknowledgment The authors' thanks are due to the Research Laboratories, Shionogi & Co., Ltd., for elemental analysis.

References and Notes

- 1) T. F. Spande, H. M. Garraffo, M. W. Edwards, H. J. C. Yeh, L. Pannell, J. W. Daly, *J. Am. Chem. Soc.*, **114**, 3475 (1992).
- 2) a) C. A. Broka, *Tetrahedron Lett.*, **34**, 3251 (1993); b) S. R. Fletcher, R. Baker, M. S. Chambers, S. C. Hobbs, P. J. Mitchell, *J. Chem. Soc., Chem. Commun.*, **1993**, 1216; c) D. F. Huang, T. Y. Shen, *Tetrahedron Lett.*, **34**, 4477 (1993); d) E. J. Corey, T.-P. Loh, S. Achyutha Rao, D. C. Daley, S. Sarshar, *J. Org. Chem.*, **58**, 5600 (1993); e) S. C. Clayton, A. C. Regan, *Tetrahedron Lett.*, **34**, 7493 (1993).
- 3) R. Kitzing, R. Fuchs, M. Joyeux, H. Prinzbach, *Helv. Chim. Acta*, **51**, 888 (1968).
- 4) a) H. Prinzbach, R. Fuchs, R. Kitzing, *Angew. Chem. Int. Ed. Engl.*, **7**, 67 (1968); b) G. P. Donnini, G. Just, *J. Heterocycl. Chem.*, **14**, 1423 (1977).
- 5) In the course of this study, the synthesis of (+)- and (–)-**1** using the corresponding *N*-BOC compound of **3** was reported.^{2b)}
- 6) K. Ninomiya, T. Shioiri, S. Yamada, *Tetrahedron*, **30**, 2151 (1974).
- 7) M.-J. Shiao, L.-M. Shyu, K.-Y. Tarn, Y.-T. Ma, *Synth. Commun.*, **1990**, 2971.
- 8) a) O. S. Tee, M. Paventi, *J. Am. Chem. Soc.*, **104**, 4142 (1982); b) M.-J. Shiao, K.-Y. Tarn, *Heterocycles*, **31**, 819 (1990).
- 9) E. M. Burgess, H. R. Penton, Jr., E. A. Taylor, *J. Org. Chem.*, **38**, 26 (1973).
- 10) a) B. E. Haskell, S. B. Bowlus, *J. Org. Chem.*, **41**, 159 (1976); b) R. C. Roemmele, H. Rapoport, *ibid.*, **53**, 2367 (1988).